ESR1 and breast cancer: The number of recognized xenoestrogens is staggering, and while previous studies have primarily focused on ERα/β, many of these compounds activate GPER, with possible consequences on neurogenic processes (53), and cancers of the breast (54), prostate (55) and digestive system (56).